– USA, TX – Shattuck Labs, Inc. (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, announced the appointment of Dr. Daniel Baker (M.D.) and Dr. Mona Ashiya (Ph.D.) to its Board of Directors.
Concurrently, Tyler Brous, Dr. Carrie Brownstein, Michael Lee, and Dr. Kate Sasser have stepped down from the Board.
About Daniel Baker, M.D.
Dr. Daniel Baker has over 20 years of drug development experience in the pharmaceutical industry. He currently serves as the interim CDO at Cue Biopharma. He has also served as CEO and Founder of KiRa Biotech Pty Ltd., a biotechnology company, and as Venture Partner at OneVentures Investments Australia, a venture capital firm, since 2019.
From 2000 to 2019, Dr. Daniel Baker served as VP, Immunology R&D at Johnson & Johnson (Janssen/Centocor), where he oversaw clinical development of Remicade, Simpon, and Stelara and contributed to more than 15 regulatory approvals in the US, Europe, and Japan. Following his retirement from Janssen in 2019,
Dr. Daniel Baker served as CEO and founder of Kira Therapeutics and, more recently, as Executive Director on the board of Galapagos Therapeutics from April 2022 until October 2024.
Dr. Daniel Baker received his Medical Degree from the University of Pennsylvania and completed his Medical Residency at Hershey Medical Center and Fellowship in Rheumatology and Immunology at the University of Pennsylvania, followed by a Research Fellowship in Rheumatology at Mass General Hospital.
About Mona Ashiya, Ph.D.
Dr. Ashiya is currently a Member at OrbiMed Advisors LLC, an investment firm, where she has served in various roles of increasing responsibility since 2010. She currently serves on the boards of directors of Disc Medicine, Inc. (NASDAQ: IRON) and several private companies.
Dr. Ashiya received her B.A. from the University of California, Berkeley, and her Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Pittsburgh.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics comes together in its lead program, SL-325, a potential first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas, and Durham, North Carolina.
For more: https://www.shattucklabs.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.